Prilosec OTC boosts P&G outlook
This article was originally published in The Tan Sheet
Executive Summary
Earnings per share for third quarter and fiscal year expected to exceed estimates by $0.01 to $0.02 due to strong organic volume growth and sales performance of Prilosec OTC and other products including Crest Whitening Expressions, firm announces March 9. P&G also announced board approval of a 2-for-1 stock split on May 21, 2004. Separately, board increases annual rate of common stock and Series A ESOP Convertible Preferred Stock dividend from $1.82 to $2.00 per share, the second dividend increase this fiscal year...